WeChat Mini Program

Old Version Features

Log in

Academic Profile User Profile

My Following Paper Collections Browse History

MRTX-500 Phase 2 Trial: Sitravatinib with Nivolumab in Patients with Nonsquamous NSCLC Progressing on or after Checkpoint Inhibitor Therapy or Chemotherapy

Kai He,David Berz,Shirish M. Gadgeel,Wade T. Iams,Debora S. Bruno,Collin M. Blakely,Alexander I. Spira,Manish R. Patel,David M. Waterhouse,Donald A. Richards,Anthony Pham,Robert Jotte,David S. Hong,Edward B. Garon,Anne Traynor, Peter Olson,Lisa Latven,Xiaohong Yan,Ronald Shazer,Ticiana A. Leal

Journal of Thoracic Oncology（2023）

Cited 21|Views33

Key words

NSCLC,Tyrosine kinase inhibitor,Sitravatinib,Nivolumab,Antitumor activity

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined